**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 87615

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Role of intelligent/interactive qualitative and quantitative analysis-three-dimensional estimated model in donor-recipient size mismatch following deceased donor liver transplantation**

Ding H *et al.* Role of IQQA-3D model in DDLT

Han Ding, Zhi-Guo Ding, Wen-Jing Xiao, Xu-Nan Mao, Qi Wang, Yi-Chi Zhang, Hao Cai, Wei Gong

**Han Ding, Yi-Chi Zhang, Hao Cai, Wei Gong,** Department of Transplantation, Xinhua Hospital, Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, China

**Zhi-Guo Ding,** Department of General Surgery, The Third People’s Hospital of Yangzhou, Yangzhou 225126, Jiangsu Province, China

**Wen-Jing Xiao,** Department of Tuberculosis Control, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China

**Xu-Nan Mao,** Department of Biliary-Pancreatic Surgery, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai 200003, China

**Qi Wang,** Department of Pathology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China

**Wei Gong,** Department of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, China

**Co-first authors:** Zhi-Guo Ding and Wen-Jing Xiao.

**Co-corresponding authors:** Hao Cai and Yi-Chi Zhang.

**Author contributions:** Gong W, Cai H and Zhang YC contributed to the study conception and design; Material preparation and data collection were performed by Ding H, Ding ZG and Wang Q; Data analysis was performed by Xiao WJ and Mao XN; The first draft of the manuscript was written by Ding H and all authors commented on previous versions of the manuscript; All authors read and approved the final manuscript. Ding ZG and Xiao WJ contributed equally to this work as co-first authors. The follow-up and data collection of 133 patients included in this study were all completed by Ding ZG, which is a time-consuming and difficult task. Therefore, it is reasonable to list him as a co-first author. The data analysis and figure drawing involved in this article were mostly completed by Xiao WJ. She maintained the rigorous principle and ensured data authenticity in the process of data analysis, which justifies her as a qualified co-first author. Cai H and Zhang YC contributed equally to this work as co-corresponding authors. Cai H consulted a large amount of relevant literature and designed this study together with Gong Wei and Zhang YC. The details of the study (such as primary outcomes, secondary outcomes, influencing factors, *etc.*) were determined by Cai H, which makes it reasonable for him to become a co-corresponding author. Zhang YC also participated in the design of the study, and as an experienced surgeon, he was mainly responsible for calculating eTLV using IQQA-3D and carrying out further amendments if necessary. In addition, he was mainly committed to revising the manuscript, which makes it reasonable for him to become a co-corresponding author.

**Supported by** National Natural Science Foundation of China, No. 82172628.

**Corresponding author: Wei Gong, Doctor, MD, PhD, Doctor, Professor, Surgeon,** Department of Transplantation, Xinhua Hospital, Affiliated to Shanghai Jiaotong University School of Medicine, No.1665 Kongjiang Road, Shanghai 200092, China. gongwei@xinhuamed.com.cn

**Received:** August 18, 2023

**Revised:** November 10, 2023

**Accepted:** November 14, 2023

**Published online:**

**Abstract**

BACKGROUND

Donor-recipient size mismatch (DRSM) is considered a crucial factor for poor outcomes in liver transplantation (LT) because of complications, such as massive intraoperative blood loss (IBL) and early allograft dysfunction (EAD). Liver volumetry is performed routinely in living donor LT, but rarely in deceased donor LT (DDLT), which amplifies the adverse effects of DRSM in DDLT. Due to the various shortcomings of traditional manual liver volumetry and formula methods, a feasible model based on intelligent/interactive qualitative and quantitative analysis-three-dimensional (IQQA-3D) for estimating the degree of DRSM is needed.

AIM

To identify benefits of IQQA-3D liver volumetry in DDLT and establish an estimation model to guide perioperative management.

METHODS

We retrospectively determined the accuracy of IQQA-3D liver volumetry for standard total liver volume (TLV) (sTLV) and established an estimation TLV (eTLV) index (eTLVi) model. Receiver operating characteristic (ROC) curves were drawn to detect the optimal cut-off values for predicting massive IBL and EAD in DDLT using donor sTLV to recipient sTLV (called sTLVi). The factors influencing the occurrence of massive IBL and EAD were explored through logistic regression analysis. Finally, the eTLVi model was compared with the sTLVi model through the ROC curve for verification.

RESULTS

A total of 133 patients were included in the analysis. The Changzheng formula was accurate for calculating donor sTLV (*P* = 0.083) but not for recipient sTLV (*P* = 0.036). Recipient eTLV calculated using IQQA-3D highly matched with recipient sTLV (*P* = 0.221). Alcoholic liver disease, gastrointestinal bleeding, and sTLVi > 1.24 were independent risk factors for massive IBL, and drug-induced liver failure was an independent protective factor for massive IBL. Male donor-female recipient combination, model for end-stage liver disease score, sTLVi ≤ 0.85, and sTLVi ≥ 1.32 were independent risk factors for EAD, and viral hepatitis was an independent protective factor for EAD. The overall survival of patients in the 0.85 < sTLVi < 1.32 group was better compared to the sTLVi ≤ 0.85 group and sTLVi ≥ 1.32 group (*P* < 0.001). There was no statistically significant difference in the area under the curve of the sTLVi model and IQQA-3D eTLVi model in the detection of massive IBL and EAD (all *P* > 0.05).

CONCLUSION

IQQA-3D eTLVi model has high accuracy in predicting massive IBL and EAD in DDLT. We should follow the guidance of the IQQA-3D eTLVi model in perioperative management.

**Key Words:** Intelligent/interactive qualitative and quantitative analysis-three-dimensional; Donor-recipient size mismatch; Intraoperative blood loss; Early allograft dysfunction

Ding H, Ding ZG, Xiao WJ, Mao XN, Wang Q, Zhang YC, Cai H, Gong W. Role of intelligent/interactive qualitative and quantitative analysis-three-dimensional estimated model in donor-recipient size mismatch following deceased donor liver transplantation. *World J Gastroenterol* 2023; In press

**Core Tip:** This is a retrospective study to identify benefits of intelligent/interactive qualitative and quantitative analysis-three-dimensional (IQQA-3D) liver volumetry in deceased donor liver transplantation and establish an estimation model to guide perioperative management. Patients with estimation total liver volume index (eTLVi) ≥ 1.24 have an increased risk of massive intraoperative blood loss and patients with eTLVi ≤ 0.85 or eTLVi ≥ 1.32 have an increased risk of early allograft dysfunction. To improve the overall survival of patients, we should follow the guidance of the IQQA-3D eTLVi model either for organ allocation or perioperative management.

**INTRODUCTION**

An understanding of the interaction between donors and recipients is crucial to ensure optimum outcomes in liver transplantation (LT)[1]. Studies have investigated the effects of mismatch in age, gender[2,3] and ethnicity[4] on the outcomes of LT, with donor-recipient size mismatch (DRSM) being the most important factor[5,6]. Nowadays, with most organ allocation systems worldwide relying on the ‘sickest first’ policy. However, they do not consider the mismatch of the mismatch of the morphological parameters in the abdominal cavity between donors and recipients[7]. Liver volumetry is rarely undertaken in deceased donor LT (DDLT), which amplifies the adverse effects of DRSM. Massive intraoperative blood loss (IBL), early allograft dysfunction (EAD)[8-10], and other complications caused by small-for-size syndrome (SFSS) or large-for-size syndrome (LFSS) have been found to lead to lower allograft survival and higher patient mortality[11,12]. Therefore, experienced centers have focused more on liver volumetry for total liver volume (TLV) and are committed to establishing a model to estimate the degree of DRSM.

The use of the Archimedes drainage method, the gold standard for liver volumetry, is restricted due to the disadvantage of measuring only for liver *in vitro*[13]. Whether TLV is calculated by height/weight or by body surface area (BSA), the results are subject to differences in race, gender, and various clinical factors[14]. Estimations by simple empirical formulas are handy and suitable for donor TLV but not for recipient TLV (mostly accompanied by ascites, hepatic carcinomas, cirrhosis, or post-hepatectomy status). Over the years, imaging equipment and visualization techniques have improved significantly and become increasingly refined. Consequently, liver volumetry, based on Doppler ultrasound (DUS), contrast-enhanced computed tomography (CT), or magnetic resonance imaging (MRI) scans, has shown a close correlation with TLV when highly trained operators spend considerable time in postprocessing analysis[15-17]. However, the expensive and time-consuming post process may impede the widespread application of non-automatic liver volumetry, particularly in some emerging transplantation centers.

With advanced technology, the trend towards automated interactive volumetry-assist software replacing manual liver volumetry in the future is anecdotally known. Intelligent/interactive qualitative and quantitative analysis-three-dimensional (IQQA-3D), one of the automated computerized liver volumetry calculators, is characterized by real accuracy, high intelligence, and robust applicability. Scattered reports[18] indicated that the advantages of high repeatability, stability, and reliability of IQQA-3D in measuring standard liver volume can reduce IBL, operative duration, and postoperative complications in precise hepatectomy and living donor LT (LDLT). However, few results have been reported on the role of IQQA-3D in liver volumetry in DDLT. Thus, we conducted this study to identify the benefits of IQQA-3D-based liver volumetry in DDLT and establish a convenient, feasible, and accurate estimation model to guide perioperative management, especially for DRSM-induced massive IBL and EAD.

**MATERIALS AND METHODS**

***Patient selection***

We retrospectively analyzed patients who underwent DDLT by a single experienced surgeon between November 2017 and February 2022 in our center and ensured that all surviving patients had been followed up for more than 1 year. All liver allografts were allocated by China Organ Transplant Response System which follows the sickest first policy. Recipients with extreme marginal allografts were excluded according to the following criteria: (1) Donors over 70 years old; (2) Severe allografts steatosis with more than 60% macrosteatosis confirmed by wedge biopsy 1 h after reperfusion; (3) The warm ischemia time of allografts of > 20 min or cold ischemia time of allografts of > 12 h; (4) Prolonged hypotension of the donors (diastolic blood pressure < 60 mmHg, maintenance time > 2 h); (5) Continuous serum total bilirubin and transaminase higher than normal by more than 3 times (maintenance time > 7 d); and (6) ABO-incompatible LT. The recipients of multiorgan transplants or liver re-transplants and recipients with missing demographic characteristics or LT-related information were also excluded.

The study was conducted in accordance with the Helsinki Declaration, and the protocol was approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (No. XHEC-D-2023-076).

***Procedures***

IQQA-3D was applied to calculate estimated TLV (eTLV) for all recipients by analyzing the imported contrast-enhanced CT/MRI scan and automatically outlining the liver parenchyma contour in each layer according to the liver anatomy and density. To improve the accuracy of eTLV, further amendments were carried out by experienced surgeons if necessary.

Donors included in this study were free of liver disease and hence the donor eTLV was similar to that of the normal population. Therefore, due to the extensive practicability for the Chinese population among existing studies, we chose the formula[19] derived by the Shanghai Changzheng Hospital to calculate donor eTLV: TLV (cm3) = 758.259 × BSA (m2) - 124.272. Standard TLV (sTLV) was preferably determined using the Archimedes method and secondly deduced from liver weight and density[20] (1.00 ± 0.06 kg/L). To estimate the degree of DRSM, the sTLV index (sTLVi), which was calculated as the ratio of donor TLV to recipient TLV, became a crucial parameter and a gold standard model in this study.

All enrolled patients underwent classic orthotopic LT without the piggyback technique, portocaval shunt, or veno-venous bypass. Anesthesiologists ensured that hypotension and hypothermia did not occur during the operation. An autotransfusion machine was used for all patients to not only maintain the concentration of blood hemoglobin but also to determine IBL. Liver allografts were weighed or volume was measured using the Archimedes method immediately after back-table procedures. Native diseased livers were subjected to the same measurement after removing the gallbladder and accessory ligaments. The donor risk index (DRI) for liver allografts was calculated using the formula described formula[21].

***Outcomes***

The primary outcomes were massive IBL and EAD caused by DRSM during the perioperative period. Massive IBL was defined as 2000 mL as the baseline. EAD was determined based on the presence of 1 or more of the following most widely accepted criteria[22]: (1) Bilirubin ≥ 10 mg/dL on post operative day 7; (2) International normalized ratio ≥ 1.6 on post operative day 7; and (3) Alanine or aspartate aminotransferase ≥ 2000 IU/L within the first 7 d.

Secondary outcomes included (1) procedure-related outcomes including tracheal extubation time, intensive care unit (ICU) stay, postoperative hospital stay, and complications, such as infection and incision nonunion; and (2) perioperative mortality and overall survival (OS) at the end of follow-up.

***Statistical analysis***

Continuous variables were expressed as mean ± SD or median (interquartile range) and categorical variables as numbers and percentages. Statistical methods used in this study included the Student’s *t*-test (or Mann-Whitney U test), Fisher’s exact test (or Pearson’s chi-square test), Kaplan-Meier method for survival analysis, and Cox regression analyses. All tests were two-sided and differences were considered statistically significant when the *P*-value was < 0.05. Receiver operating characteristic (ROC) curves were drawn to not only detect the optimal cut-off values for the index but also confirm the equivalence of the sTLVi model and the eTLV index (eTLVi) model in predicting massive IBL and EAD. Univariate and multivariable logistic regression analyses were performed successively to predict how sTLVi affected the development of massive IBL and EAD.

**RESULTS**

***Demographics of recipients and donors***

A total of 133 patients were enrolled in this study. Patients with chronic hepatitis B virus/hepatitis C virus (HBV/HCV) infection accounted for the majority (63.9%) of the patients, followed by those with chronic alcoholic liver disease (ALD) (18.0%) and drug-induced liver failure (DILF) (9.0%; Table 1). Gastrointestinal bleeding (64.7%), ascites (51.9%), and hepatic encephalopathy (23.3%) were the most common clinical symptoms in the included patients. Pathologically confirmed hepatic carcinomas were found in 42 removed livers (31.6%). Twenty-eight patients (21.1%) used to undergo open upper abdominal surgery and 29 patients (21.8%) had a history of one or more artificial liver support system (ALSS) use.

Donors were younger (mean age, 48.1 ± 13.1 years *vs* 49.4 ± 12.8 years, *P* = 0.388) than recipients and had a higher proportion of males (83.5% *vs* 76.7%, *P* = 0.002). Although the body shape of recipients was generally smaller than that of donors, which was reflected in mean height (168.1 ± 10.2 cm *vs* 170.6 ± 11.2 cm, *P* = 0.032) and mean weight (67.5 ± 18.0 kg *vs* 73.7 ± 17.5 kg, *P* = 0.003), there was no statistical difference in sTLV of recipients and donors (1299 ± 482 mL *vs* 1311 ± 267 mL, *P* = 0.799). Notably, considering the shortage of donor pool in China, 23 liver allografts with HBV or HCV infection (17.3%) and 43 allografts with mild or moderate steatosis (32.3%) were transplanted after exclusion of extreme marginal allografts through a rapid biopsy. The mean DRI of liver allografts was 2.28 ± 0.42. Male donor-female recipient (MD-FR) combination and female donor-male recipient (FD-MR) combination were observed in 26 cases (19.5%) and 17 cases (12.8%), respectively, which were also considered for our analyses.

***Operational parameters and outcomes***

The mean cold ischemia time was 5.9 ± 1.8 h, and the mean anhepatic phase time was 50.7 ± 9.0 min. Massive IBL developed in 71.4% of recipients with a mean IBL of 3117 ± 1725 mL and a mean intraoperative blood transfusion (IBT) of 1949 ± 1749 mL. The median tracheal extubation time, ICU stay, and postoperative hospital stay were 1 (1-3) d, 2 (1-6) d, and 15 (11-23) d, respectively. EAD developed in 42.1% of recipients, of which SFSS was the cause in 36 recipients (27.1%) and LFSS was the cause in 20 recipients (15.0%). Infection occurred in 36.8% of recipients, and incision nonunion occurred in 21.8%. In terms of perioperative adverse events, there were 29 perioperative deaths (21.8%), including 7 blood loss-specific deaths (5.3%), and 17 EAD-specific deaths (12.8%).

***Accuracy of IQQA-3D and the formula method for calculating donor and recipient eTLV***

Compared with donor sTLV, there was no statistical difference in donor eTLV calculated using the Changzheng formula (1287 ± 207 mL *vs* 1311 ± 267 mL, *P* = 0.083). However, compared with recipient sTLV, the Changzheng formula for calculating recipient eTLV was not accurate (1213 ± 212 mL *vs* 1299 ± 482 mL, *P* = 0.036), while recipient eTLV calculated using IQQA-3D was highly matched up with recipient sTLV (1311 ± 522 mL *vs* 1299 ± 482 mL, *P* = 0.221). Therefore, the IQQA-3D eTLVi model was defined as the ratio of donor eTLV to IQQA-3D recipient eTLV and selected as an estimation model in the study.

***Association between sTLVi and massive IBL***

Univariate logistic regression revealed that sTLVi was a risk factor for massive IBL [odds ratio (OR) = 2.968, *P* = 0.037]. The optimal cut-off value of sTLVi in predicting massive IBL calculated using the ROC curve was 1.24, with a sensitivity of 46.3% and a specificity of 94.7% (Figure 1A). Except for a higher proportion of males (82.8% *vs* 65.2%, *P* = 0.023) in the sTLVi < 1.24 group, there was no significant statistical difference in other recipient characteristics (all *P* > 0.05). The distribution of donor characteristics was similar, except for the MD-FR combination (11.5% *vs* 34.8%, *P* = 0.001) and allograft steatosis (25.3% *vs* 45.7%, *P* = 0.017). In addition, the sTLVi < 1.24 group showed advantages in terms of the anhepatic phase time (49.3 ± 7.2 min *vs* 53.6 ± 11.4 min, *P* = 0.024), IBL (2430 ± 1203 mL *vs* 4417 ± 1821 mL, *P* < 0.001), and IBT (1366 ± 1235 mL *vs* 3052 ± 2039 mL, *P* < 0.001). In terms of recovery course, the sTLVi < 1.24 group had a longer survival time (45.6 ± 2.8 mo *vs* 37.0 ± 4.1 mo, *P* = 0.132), and shorter tracheal extubation time (median, 1 d *vs* 2 d, *P* = 0.089), ICU stay (median, 2 d *vs* 3 d, *P* = 0.082) and postoperative hospital stay (median, 15 d *vs* 16 d, *P* = 0.239) than the sTLVi ≥ 1.24 group. These data were not statistically significant except for blood loss-specific mortality (1.1% *vs* 13.0%, *P* = 0.007).

The results of multivariate logistic regression analysis revealed that sTLVi ≥ 1.24 (OR = 18.43, *P* < 0.001), ALD (OR = 9.371, *P* = 0.040) and gastrointestinal bleeding (OR = 3.954, *P* = 0.005) were associated with massive IBL, while DILF (OR = 0.226, *P* = 0.047) was protective against massive IBL (Table 2).

***Association between sTLVi with EAD***

Unconventional sTLVi was found to be related to an increased risk of EAD (*P* < 0.001). The optimal cut-off values of sTLVi calculated using the ROC curve for predicting EAD caused by SFSS and LFSS were 0.85 (sensitivity 96.0%, specificity 88.0%) and 1.32 (sensitivity 95.0%, specificity 85.0%), respectively (Figure 1B and C). In the sTLVi ≥ 1.32 group, there were significant differences in the proportion of males (61.1% *vs* 83.8% and 81.7%, *P* = 0.034), MD-FR combination (41.7% *vs* 8.1% and 13.3%, *P* < 0.001), and allograft steatosis (50.0% *vs* 13.5% and 33.3%, *P* = 0.004) compared to the 0.85< sTLVi <1.32 group and the sTLVi ≤ 0.85 group. The mean Child-Pugh score for patients in the 0.85 < sTLVi < 1.32 group was the lowest among the 3 groups (8.2 ± 2.8 *vs* 9.6 ± 2.8 and 9.4 ± 2.7, *P* = 0.033). The distribution of other characteristics was similar between the 3 groups, except for the prolonged anhepatic phase time with the increase of sTLVi (*P* = 0.002).

An sTLVi of ≤ 0.85 (OR = 21234, *P* < 0.001) and model for end-stage liver disease (MELD) score (OR = 1.333, *P* = 0.002) were associated with EAD caused by SFSS, whereas HBV/HCV (OR = 0.095, *P* = 0.042) infection was protective against EAD on multivariate logistic regression (Table 3). An sTLVi of ≥ 1.32 (OR = 78.56, *P* < 0.001) and MD-FR combination (OR = 6.540, *P* = 0.008) were associated with EAD caused by LFSS on multivariate logistic regression.

In general, patients with sTLVi between 0.85 and 1.32 had a longer survival time (52.5 ± 2.6 mo *vs* 37.3 ± 4.4 mo and 25.0 ± 4.3 mo, *P* < 0.001), shorter tracheal extubation time (median, 1 d *vs* 1 d and 2 d, *P* = 0.002), lower EAD-associated morbidity (3.4% *vs* 64.9% and 52.8%, *P* < 0.001) and lower EAD-specific mortality (1.7% *vs* 13.5% and 30.6%, *P* < 0.001) compared to the sTLVi ≥ 1.32 group and the sTLVi ≤ 0.85 group. However, the sTLVi did not influence ICU stay (*P* = 0.383) and postoperative hospital stay (*P* = 0.101). There were significant differences in terms of median survival time between the 3 groups (median, 57 mo *vs* 60 mo *vs* 24 mo, *P* < 0.001). Figure 2 shows that the OS of patients with sTLVi between 0.85 and 1.32 was significantly superior to those with sTLVi ≤ 0.85 (*P* = 0.006) and sTLVi ≥ 1.32 (*P* < 0.001).

***Equivalence between the sTLVi model and IQQA-3D******eTLVi model***

The area under the curve (AUC) of the sTLVi and IQQA-3D eTLVi models for the detection of massive IBL were 0.618 and 0.598 (Z = 0.889, *P* = 0.374; Figure 3A), respectively. The AUC of the sTLVi model and IQQA-3D eTLVi model for predicting EAD caused by SFSS and LFSS were 0.932 and 0.889 (*Z* = 1.501, *P* = 0.133), 0.933 and 0.922 (Z = 0.710, *P* = 0.478), respectively (Figure 3B and C). There were no statistically significant differences in the AUC of the sTLVi model and IQQA-3D eTLVi model for predicting massive IBL and EAD. Finally, we found that the IQQA-3D eTLVi model was also applicable to all optimal cut-off values and was equivalent to the sTLVi model in predicting massive IBL and EAD after verification.

**DISCUSSION**

Postoperative complications associated with DRSM have been reported in an increasing number of DDLT studies[8-12,23]. Conclusions drawn from LDLT-related studies are that sTLVi < 0.5 is associated with poor outcomes[24] and cannot be used for DRSM in DDLT because additional risk factors, such as brain death and longer preservation injury, result in the need for a larger allograft in DDLT. Therefore, this study aimed to establish an easy, feasible, and accurate estimation model using IQQA-3D to predict massive IBL and EAD associated with DRSM and guide perioperative management in DDLT.

Massive IBT has been reported to possibly increase the risk of acute renal failure, surgical site infections, and recurrence of hepatic carcinomas in patients[25-27]. McCluskey *et al.*’s[28] and *et al.*’s[29] attempt to create a model to predict the demand for IBT based on preoperative variables was not successful. The influence of preoperative risk factors and surgical factors on massive IBL have been widely studied[30], but donor factors were rarely mentioned. We have concluded that sTLVi ≥ 1.24 is an independent risk factor for massive IBL, which has not been reported in existing literatures. This may be attributed to the greater surgical difficulty and longer anhepatic phase time. In addition, the probability of large allografts accompanied by steatosis is higher than that of small allografts, which was seen in our analysis. Theoretically, a large allograft can fill the abdominal space to tamponade of bleeding, but allograft steatosis can have a greater effect on massive IBL due to the delayed recovery of coagulation function after reperfusion.

Besides DRSM, we observed that ALD and gastrointestinal bleeding were independent risk factors for massive IBL. Patients with ALD always experience a long course of liver disease and usually experience portal hypertension, plentiful collateral circulation, and cavernous transformation of the portal vein. Gastrointestinal bleeding can serve as a significant marker of portal hypertension, indicating a greater likelihood of multiple thin and varicose blood vessels being transected during surgical dissection. Animal experiments have shown that replacing the exact IBL volume results in an increase in portal pressure by 20%[31], higher rates of massive IBL, and worse outcome[32] in portal hypertensive rats subjected to a period of gastrointestinal bleeding. This has subsequently been demonstrated in our study, as adequate IBT was usually given to recipients with gastrointestinal bleeding before transplantation to correct hypovolemia. Surprisingly, we observed that DILF, a severe liver disease characterized by rapid onset and progression, has become an independent protective factor for massive IBL. Since patients with DILF rarely show anatomic changes in the native liver, the incidence of massive IBL can be reduced with a shorter hepatectomy duration, which is consistent with other reports[33].

Studies have reported factors related to EAD, with the most important being ischemia-reperfusion injury (IRI), which is difficult to regulate. We found that improper sTLVi is associated with an increased risk of EAD and this effect is ‘U’ shaped. Due to the unavailability of an index to quantify the magnitude of the DRSM effect and of a statistical methodology to formulate the model for describing its nonlinear effect, scattered studies[5,10] only reported the impact of SFSS or LFSS on EAD separately. To overcome the statistical difficulty, we divided recipients into 3 groups and found that the effect on EAD becomes stronger toward both ends of sTLVi values.

MELD score and sTLVi ≤ 0.85 were independent risk factors for EAD caused by SFSS. SFSS occurs when the functional liver volume is too small to provide enough activated hepatocytes for hepatic metabolism. Moreover, the small allograft will withstand the entire blood flow of the original liver, leading to severe congestion of the hepatic sinuses and portal hypertension after reperfusion. MELD score has been reported by various authors as an independent risk factor for the occurrence of EAD in DDLT recipients[34,35], which is consistent with our conclusion.

The MD-FR combination and sTLVi ≥ 1.32 were independent risk factors for EAD caused by LFSS. Patients with sTLVi ≥ 1.32 underwent a higher number of challenging surgeries, had longer anhepatic phase time, and had a higher probability of allograft steatosis, which aggravated IRI. Other anatomical causes of LFSS-related EAD included external compression affecting allograft perfusion and outflow tract obstruction, which were also potential factors with the lowest median survival time in the sTLVi ≥ 1.32 group. In terms of secondary outcomes, the tracheal extubation time in the sTLVi ≥ 1.32 group was longer than that in the other 2 groups, indicating the potential impact of large volume allograft on respiratory complications, consistent with Levesque *et al.*’s report[6]. Gender mismatch, especially the FD-MR combination, has been reported in most studies as an independent risk factor for EAD[2,36,37]. Hormonal factors and differences in IRI and SFSS are the main hypotheses currently[38]. It is speculated that female allografts face a greater risk of IRI due to the sudden loss of protection from estrogen during implantation[2]. However, in our study, the MD-FR combination rather than the FD-MR combination played a significant role in EAD, size which could be related to the differences among males and females.

Because of time constraints with organ allocation and limited services at the donor hospital, donor eTLV measured using cross-sectional imaging is usually not feasible. We confirmed the accuracy of the Changzheng formula method in calculating donor eTLV rather than recipient eTLV. Therefore, we focused on IQQA-3D because of its high accuracy, shorter time, and not having to rely on experienced operators[39,40]. Foreign studies[41] have reported the application of IQQA-3D in precise hepatectomy and LDLT, which not only shortens the operation time but also reduces IBL and other complications. The application of IQQA-3D was rarely reported in DDLT. However, our study has innovatively used IQQA-3D into the eTLVi model after demonstrating its accuracy in measuring recipient eTLV and confirmed its equivalence with the sTLVi model in predicting massive IBL and EAD. For patients with stable liver diseases, the IQQA-3D eTLVi model can be used to exclude extremely sized mismatched allografts. For patients with critical diseases having minimal choice but to receive unsuitable allografts, timely and sufficient perioperative management can suppress adverse outcomes. For patients with eTLVi ≥ 1.24, sufficient blood products, antifibrinolytics, terlipressin, autotransfusion machine, and liver resection time should be prepared for and reserved before DDLT to reduce IBL. For patients with eTLVi ≤ 0.85, the intraoperative ligation of the splenic artery or resection of the spleen should be considered to control the velocity of the portal vein. Also, if necessary, ALSS therapy should be performed promptly to reduce the burden of the allografts. For patients with eTLVi ≥ 1.32, in addition to sufficient preoperative treatments to reduce the Child-Pugh score and MELD score, strict respiratory management and frequent DUS monitoring to prevent vascular complications, reduced-size LT should be considered.

To improve the accuracy of the results of this impact, we first used sTLVi calculated using the Archimedes method as the gold standard instead of the formula method based on BSA[9,42,43] or graft-to-recipient weight ratio[6,44]. If a simpler or more accurate liver volumetry tool other than IQQA-3D is developed in the future, researchers can still create a new eTLVi model to compare with the sTLVi model in our study. However, like the shortcomings of other studies on DRSM, we only compared TLV between donors and recipients, but failed to compare the abdominal parameters in detail. Due to the limitations of a single-center retrospective study without numerous patients and sufficient follow-up time, future prospective studies are warranted to carried out.

**CONCLUSION**

We established the IQQA-3D eTLVi model to estimate the degree of DRSM and predict massive IBL and EAD in DDLT. Patients with eTLVi ≥ 1.24 have an increased risk of massive IBL and patients with eTLVi ≤ 0.85 or eTLVi ≥ 1.32 have an increased risk of EAD. To improve the OS of patients, we should follow the guidance of the IQQA-3D eTLVi model either for organ allocation or perioperative management.

**ARTICLE HIGHLIGHTS**

***Research background***

Donor-recipient size mismatch (DRSM) is considered a crucial factor for poor outcomes in deceased donor liver transplantation (DDLT).

***Research motivation***

A feasible model for estimating the degree of DRSM is needed.

***Research objectives***

To identify benefits of intelligent/interactive qualitative and quantitative analysis-three-dimensional (IQQA-3D) liver volumetry in DDLT and establish an estimation model to guide perioperative management.

***Research methods***

A retrospective study was conducted to determine the accuracy of IQQA-3D liver volumetry and to establish an estimation total liver volume (TLV) index (eTLVi) model. Receiver operating characteristic curves and logistic regression analysis were used to detect the influencing factors for the occurrence of massive intraoperative blood loss (IBL) and early allograft dysfunction (EAD) in DDLT.

***Research results***

Recipient estimation TLV calculated using IQQA-3D highly matched with recipient standard TLV (*P* = 0.221). Alcoholic liver disease, gastrointestinal bleeding, and standard TLV index (sTLVi) > 1.24 were independent risk factors for massive IBL, and drug-induced liver failure was an independent protective factor for massive IBL. Male donor-female recipient combination, model for end-stage liver disease score, sTLVi ≤ 0.85, and sTLVi ≥ 1.32 were independent risk factors for EAD, and viral hepatitis was an independent protective factor for EAD. The overall survival of patients in the 0.85 < sTLVi < 1.32 group was better compared to the sTLVi ≤ 0.85 group and sTLVi ≥ 1.32 group (*P* < 0.001). There was no statistically significant difference in the area under the curve of the sTLVi model and IQQA-3D eTLVi model in the detection of massive IBL and EAD (all *P* > 0.05).

***Research conclusions***

IQQA-3D eTLVi model has high accuracy in predicting massive IBL and EAD in DDLT. We should follow the guidance of the IQQA-3D eTLVi model in perioperative management.

***Research perspectives***

By establishing the eTLVi model, the degree of DRSM was estimated and IQQA-3D proved to be of guiding value in perioperative management in DDLT.

**ACKNOWLEDGEMENTS**

The authors gratefully acknowledge all the doctors who collaborated on this project by collecting data.

**REFERENCES**

1 **Reddy MS**, Varghese J, Venkataraman J, Rela M. Matching donor to recipient in liver transplantation: Relevance in clinical practice. *World J Hepatol* 2013; **5**: 603-611 [PMID: 24303088 DOI: 10.4254/wjh.v5.i11.603]

2 **Lai Q**, Giovanardi F, Melandro F, Larghi Laureiro Z, Merli M, Lattanzi B, Hassan R, Rossi M, Mennini G. Donor-to-recipient gender match in liver transplantation: A systematic review and meta-analysis. *World J Gastroenterol* 2018; **24**: 2203-2210 [PMID: 29853738 DOI: 10.3748/wjg.v24.i20.2203]

3 **Germani G**, Zeni N, Zanetto A, Adam R, Karam V, Belli LS, O'Grady J, Mirza D, Klempnauer J, Cherqui D, Pratschke J, Jamieson N, Salizzoni M, Hidalgo E, Lerut J, Paul A, Garcia-Valdecasas JC, Rodríguez FSJ, Villa E, Burra P; European Liver, Intestine Transplant Association (ELITA). Influence of donor and recipient gender on liver transplantation outcomes in Europe. *Liver Int* 2020; **40**: 1961-1971 [PMID: 32418358 DOI: 10.1111/liv.14510]

4 **Zhang Y**. Impact of Donor Recipient Gender and Race Mismatch on Graft Outcomes in Patients With End-Stage Liver Disease Undergoing Liver Transplantation. *Prog Transplant* 2017; **27**: 39-47 [PMID: 27895103 DOI: 10.1177/1526924816679839]

5 **Tanaka K**, Ogura Y. "Small-for-size graft" and "small-for-size syndrome" in living donor liver transplantation. *Yonsei Med J* 2004; **45**: 1089-1094 [PMID: 15627301 DOI: 10.3349/ymj.2004.45.6.1089]

6 **Levesque E**, Duclos J, Ciacio O, Adam R, Castaing D, Vibert E. Influence of larger graft weight to recipient weight on the post-liver transplantation course. *Clin Transplant* 2013; **27**: 239-247 [PMID: 23293941 DOI: 10.1111/ctr.12059]

7 **Tschuor C**, Ferrarese A, Kuemmerli C, Dutkowski P, Burra P, Clavien PA; Liver Allocation Study Group. Allocation of liver grafts worldwide - Is there a best system? *J Hepatol* 2019; **71**: 707-718 [PMID: 31199941 DOI: 10.1016/j.jhep.2019.05.025]

8 **Fukazawa K**, Nishida S, Volsky A, Tzakis AG, Pretto EA Jr. Body surface area index predicts outcome in orthotopic liver transplantation. *J Hepatobiliary Pancreat Sci* 2011; **18**: 216-225 [PMID: 20936303 DOI: 10.1007/s00534-010-0334-9]

9 **Croome KP**, Lee DD, Saucedo-Crespo H, Burns JM, Nguyen JH, Perry DK, Taner CB. A novel objective method for deceased donor and recipient size matching in liver transplantation. *Liver Transpl* 2015; **21**: 1471-1477 [PMID: 26358746 DOI: 10.1002/lt.24333]

10 **Shen Z**, Wang Z, Jiang Y, Wu T, Zheng S. Early outcomes of implanting larger-sized grafts in deceased donor liver transplantation. *ANZ J Surg* 2020; **90**: 1352-1357 [PMID: 32691510 DOI: 10.1111/ans.16132]

11 **Reyes J**, Perkins J, Kling C, Montenovo M. Size mismatch in deceased donor liver transplantation and its impact on graft survival. *Clin Transplant* 2019; **33**: e13662 [PMID: 31283049 DOI: 10.1111/ctr.13662]

12 **Allard MA**, Lopes F, Frosio F, Golse N, Sa Cunha A, Cherqui D, Castaing D, Adam R, Vibert E. Extreme large-for-size syndrome after adult liver transplantation: A model for predicting a potentially lethal complication. *Liver Transpl* 2017; **23**: 1294-1304 [PMID: 28779555 DOI: 10.1002/lt.24835]

13 **Yu HC**, You H, Lee H, Jin ZW, Moon JI, Cho BH. Estimation of standard liver volume for liver transplantation in the Korean population. *Liver Transpl* 2004; **10**: 779-783 [PMID: 15162473 DOI: 10.1002/Lt.20188]

14 **Pomposelli JJ**, Tongyoo A, Wald C, Pomfret EA. Variability of standard liver volume estimation *vs* software-assisted total liver volume measurement. *Liver Transpl* 2012; **18**: 1083-1092 [PMID: 22532341 DOI: 10.1002/lt.23461]

15 **Choi SH**, Kwon JH, Kim KW, Jang HY, Kim JH, Kwon HJ, Lee J, Song GW, Lee SG. Measurement of liver volumes by portal vein flow by Doppler ultrasound in living donor liver transplantation. *Clin Transplant* 2017; **31** [PMID: 28681460 DOI: 10.1111/ctr.13050]

16 **Schroeder T**, Malagó M, Debatin JF, Goyen M, Nadalin S, Ruehm SG. "All-in-one" imaging protocols for the evaluation of potential living liver donors: comparison of magnetic resonance imaging and multidetector computed tomography. *Liver Transpl* 2005; **11**: 776-787 [PMID: 15973711 DOI: 10.1002/lt.20429]

17 **Haimerl M**, Schlabeck M, Verloh N, Zeman F, Fellner C, Nickel D, Barreiros AP, Loss M, Stroszczynski C, Wiggermann P. Volume-assisted estimation of liver function based on Gd-EOB-DTPA-enhanced MR relaxometry. *Eur Radiol* 2016; **26**: 1125-1133 [PMID: 26186960 DOI: 10.1007/s00330-015-3919-5]

18 **Mise Y**, Tani K, Aoki T, Sakamoto Y, Hasegawa K, Sugawara Y, Kokudo N. Virtual liver resection: computer-assisted operation planning using a three-dimensional liver representation. *J Hepatobiliary Pancreat Sci* 2013; **20**: 157-164 [PMID: 23135735 DOI: 10.1007/s00534-012-0574-y]

19 **Feng LM**, Wang PQ, Yu H, Chen RT, Wang J, Sheng X, Yuan ZL, Shi PM, Xie WF, Zeng X. New formula for predicting standard liver volume in Chinese adults. *World J Gastroenterol* 2017; **23**: 4968-4977 [PMID: 28785151 DOI: 10.3748/wjg.v23.i27.4968]

20 **Yuan D**, Lu T, Wei YG, Li B, Yan LN, Zeng Y, Wen TF, Zhao JC. Estimation of standard liver volume for liver transplantation in the Chinese population. *Transplant Proc* 2008; **40**: 3536-3540 [PMID: 19100432 DOI: 10.1016/j.transproceed.2008.07.135]

21 **Feng S**, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, Greenstein SM, Merion RM. Characteristics associated with liver graft failure: the concept of a donor risk index. *Am J Transplant* 2006; **6**: 783-790 [PMID: 16539636 DOI: 10.1111/j.1600-6143.2006.01242.x]

22 **Olthoff KM**, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, Shaked A, Christie JD. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. *Liver Transpl* 2010; **16**: 943-949 [PMID: 20677285 DOI: 10.1002/lt.22091]

23 **Fukazawa K**, Nishida S. Size mismatch in liver transplantation. *J Hepatobiliary Pancreat Sci* 2016; **23**: 457-466 [PMID: 27474079 DOI: 10.1002/jhbp.371]

24 **Kiuchi T**, Kasahara M, Uryuhara K, Inomata Y, Uemoto S, Asonuma K, Egawa H, Fujita S, Hayashi M, Tanaka K. Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. *Transplantation* 1999; **67**: 321-327 [PMID: 10075602 DOI: 10.1097/00007890-199901270-00024]

25 **Reichert B**, Kaltenborn A, Becker T, Schiffer M, Klempnauer J, Schrem H. Massive blood transfusion after the first cut in liver transplantation predicts renal outcome and survival. *Langenbecks Arch Surg* 2014; **399**: 429-440 [PMID: 24682384 DOI: 10.1007/s00423-014-1181-y]

26 **Freire MP**, Soares Oshiro IC, Bonazzi PR, Guimarães T, Ramos Figueira ER, Bacchella T, Costa SF, Carneiro D'Albuquerque LA, Abdala E. Surgical site infections in liver transplant recipients in the model for end-stage liver disease era: an analysis of the epidemiology, risk factors, and outcomes. *Liver Transpl* 2013; **19**: 1011-1019 [PMID: 23744748 DOI: 10.1002/lt.23682]

27 **Kornberg A**, Witt U, Kornberg J, Ceyhan GO, Mueller K, Friess H, Thrum K. Prognostic Impact of Intraoperative Blood Loss in Liver Transplant Patients with Advanced Hepatocellular Carcinoma. *Anticancer Res* 2016; **36**: 5355-5364 [PMID: 27798899 DOI: 10.21873/anticanres.11109]

28 **McCluskey SA**, Karkouti K, Wijeysundera DN, Kakizawa K, Ghannam M, Hamdy A, Grant D, Levy G. Derivation of a risk index for the prediction of massive blood transfusion in liver transplantation. *Liver Transpl* 2006; **12**: 1584-1593 [PMID: 16952177 DOI: 10.1002/Lt.20868]

29 **Cywinski JB**, Alster JM, Miller C, Vogt DP, Parker BM. Prediction of intraoperative transfusion requirements during orthotopic liver transplantation and the influence on postoperative patient survival. *Anesth Analg* 2014; **118**: 428-437 [PMID: 24445640 DOI: 10.1213/ANE.0b013e3182a76f19]

30 **Cleland S**, Corredor C, Ye JJ, Srinivas C, McCluskey SA. Massive haemorrhage in liver transplantation: Consequences, prediction and management. *World J Transplant* 2016; **6**: 291-305 [PMID: 27358774 DOI: 10.5500/wjt.v6.i2.291]

31 **Kravetz D**, Sikuler E, Groszmann RJ. Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. *Gastroenterology* 1986; **90**: 1232-1240 [PMID: 3956942 DOI: 10.1016/0016-5085(86)90390-2]

32 **Castañeda B**, Morales J, Lionetti R, Moitinho E, Andreu V, Pérez-Del-Pulgar S, Pizcueta P, Rodés J, Bosch J. Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats. *Hepatology* 2001; **33**: 821-825 [PMID: 11283845 DOI: 10.1053/jhep.2001.23437]

33 **Rana A**, Petrowsky H, Hong JC, Agopian VG, Kaldas FM, Farmer D, Yersiz H, Hiatt JR, Busuttil RW. Blood transfusion requirement during liver transplantation is an important risk factor for mortality. *J Am Coll Surg* 2013; **216**: 902-907 [PMID: 23478547 DOI: 10.1016/j.jamcollsurg.2012.12.047]

34 **Ito T**, Naini BV, Markovic D, Aziz A, Younan S, Lu M, Hirao H, Kadono K, Kojima H, DiNorcia J 3rd, Agopian VG, Yersiz H, Farmer DG, Busuttil RW, Kupiec-Weglinski JW, Kaldas FM. Ischemia-reperfusion injury and its relationship with early allograft dysfunction in liver transplant patients. *Am J Transplant* 2021; **21**: 614-625 [PMID: 32713098 DOI: 10.1111/ajt.16219]

35 **Grąt M**, Wronka KM, Patkowski W, Stypułkowski J, Grąt K, Krasnodębski M, Masior Ł, Lewandowski Z, Krawczyk M. Effects of Donor Age and Cold Ischemia on Liver Transplantation Outcomes According to the Severity of Recipient Status. *Dig Dis Sci* 2016; **61**: 626-635 [PMID: 26499986 DOI: 10.1007/s10620-015-3910-7]

36 **Rustgi VK**, Marino G, Halpern MT, Johnson LB, Umana WO, Tolleris C. Role of gender and race mismatch and graft failure in patients undergoing liver transplantation. *Liver Transpl* 2002; **8**: 514-518 [PMID: 12037781 DOI: 10.1053/jlts.2002.33457]

37 **Uemura T**, Randall HB, Sanchez EQ, Ikegami T, Narasimhan G, McKenna GJ, Chinnakotla S, Levy MF, Goldstein RM, Klintmalm GB. Liver retransplantation for primary nonfunction: analysis of a 20-year single-center experience. *Liver Transpl* 2007; **13**: 227-233 [PMID: 17256780 DOI: 10.1002/Lt.20992]

38 **Francavilla A**, di Leo A, Eagon PK, Wu SQ, Ove P, van Thiel DH, Starzl TE. Regenerating rat liver: correlations between estrogen receptor localization and deoxyribonucleic acid synthesis. *Gastroenterology* 1984; **86**: 552-557 [PMID: 6693017]

39 **Suzuki K**, Epstein ML, Kohlbrenner R, Garg S, Hori M, Oto A, Baron RL. Quantitative radiology: automated CT liver volumetry compared with interactive volumetry and manual volumetry. *AJR Am J Roentgenol* 2011; **197**: W706-W712 [PMID: 21940543 DOI: 10.2214/AJR.10.5958]

40 **Bozkurt B**, Emek E, Arikan T, Ceyhan O, Yazici P, Sahin T, Mammadov E, Serin A, Gurcan NI, Yuzer Y, Tokat Y. Liver Graft Volume Estimation by Manual Volumetry and Software-Aided Interactive Volumetry: Which is Better? *Transplant Proc* 2019; **51**: 2387-2390 [PMID: 31324483 DOI: 10.1016/j.transproceed.2019.01.152]

41 **Müller SA**, Bläuer K, Kremer M, Thorn M, Mehrabi A, Meinzer HP, Hinz U, Metzger J, Büchler MW, Schmied BM. Exact CT-based liver volume calculation including nonmetabolic liver tissue in three-dimensional liver reconstruction. *J Surg Res* 2010; **160**: 236-243 [PMID: 19765736 DOI: 10.1016/j.jss.2009.04.050]

42 **Fukazawa K**, Yamada Y, Nishida S, Hibi T, Arheart KL, Pretto EA Jr. Determination of the safe range of graft size mismatch using body surface area index in deceased liver transplantation. *Transpl Int* 2013; **26**: 724-733 [PMID: 23647566 DOI: 10.1111/tri.12111]

43 **Vauthey JN**, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, Hicks M, Alsfasser G, Lauwers G, Hawkins IF, Caridi J. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. *Surgery* 2000; **127**: 512-519 [PMID: 10819059 DOI: 10.1067/msy.2000.105294]

44 **Lo CM**, Fan ST, Liu CL, Chan JK, Lam BK, Lau GK, Wei WI, Wong J. Minimum graft size for successful living donor liver transplantation. *Transplantation* 1999; **68**: 1112-1116 [PMID: 10551638 DOI: 10.1097/00007890-199910270-00009]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Ethics Committee of Xinhua Hospital Affifiliated to Shanghai Jiao Tong University School of Medicine (No. XHEC-D-2023-076).

**Informed consent statement:** All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.

**Conflict-of-interest statement:** The authors have no relevant financial or non-financial interests to disclose.

**Data sharing statement:** Technical appendix, statistical code, and dataset available from the corresponding author at gongwei@xinhuamed.com.cn.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 18, 2023

**First decision:** November 3, 2023

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Abbas Z, Pakistan; Ferreira GSA, Brazil **S-Editor:** Lin C **L-Editor: P-Editor:**

**Figure Legends**



**Figure 1** **Optimal cut-off values of the index in predicting massive intraoperative blood loss and early allograft dysfunction.** A: The standard total liver volume index (sTLVi) value of 1.24 was the optimal cutoff value for predicting massive intraoperative blood loss, with a sensitivity of 46.3% and a specificity of 94.7%; B: The sTLVi value of 0.85 was the optimal cutoff value for predicting early allograft dysfunction (EAD) caused by small-for-size syndrome, with a sensitivity of 96.0% and a specificity of 88.0%; C: The sTLVi value of 1.32 was the optimal cutoff value for predicting EAD caused by large-for-size syndrome, with a sensitivity of 95.0% and a specificity of 85.0%. ROC: Receiver operating characteristic.



**Figure 2 Overall survival of patients in 0.85 < standard total liver volume index < 1.32 group was significantly superior to those in standard total liver volume index ≤ 0.85 group (*P* = 0.006) and sTLVi ≥ 1.32 group (*P* < 0.001).** sTLVi: Standard total liver volume index.



**Figure 3 The equivalence of the standard total liver volume index model and the estimation total liver volume index model in predicting** **massive intraoperative blood loss and early allograft dysfunction.** A: The area under the curve (AUC) of standard total liver volume index (sTLVi) model and intelligent/interactive qualitative and quantitative analysis-three-dimensional (IQQA-3D) estimation total liver volume index (eTLVi) model in detection of massive IBL were 0.618 and 0.598 (*Z* = 0.889，*P* = 0.374), demonstrating equivalence; B: The AUC of sTLVi model and IQQA-3D eTLVi model in detection of early allograft dysfunction (EAD) caused by small-for-size syndrome were 0.932 and 0.889 (*Z* = 1.501，*P* = 0.133), demonstrating equivalence; C: The AUC of sTLVi model and IQQA-3D eTLVi model in detection of EAD caused by large-for-size syndrome were 0.933 and 0.922 (*Z* = 0.710，*P* = 0.478), demonstrating equivalence. eTLVi: estimation total liver volume index; sTLVi: Standard total liver volume index; ROC: Receiver operating characteristic.

**Table 1 Demographics, operational parameters and outcomes of recipients and donors**

|  |  |  |
| --- | --- | --- |
|  | **Recipient** | **Donor** |
| **Demographics** |  |  |
| Age (yr) | 49.4 ± 12.8 | 48.1 ± 13.1 |
| Male | 102 (76.7) | 111 (83.5) |
| Height (cm) | 168.1 ± 10.2 | 170.6 ± 11.2 |
| Weight (kg) | 67.5 ± 18.0 | 73.7 ± 17.5 |
| sTLV (mL) | 1299 ± 482 | 1311 ± 267 |
| eTLV by formula (mL) | 1213 ± 212 | 1287 ± 207 |
| eTLV by IQQA-3D (mL) | 1311 ± 522 | - |
| DRI | - | 2.28 ± 0.42 |
| Cold ischemia time (h) | - | 5.9 ± 1.8 |
| **Liver disease** |  |  |
| HBV/HCV | 85 (63.9) | 23 (17.3) |
| ALD | 24 (18.0) | 0 |
| DILF | 12 (9.0) | 0 |
| Steatosis | 8 (6.0) | 43 (32.3) |
| Hepatic carcinoma | 42 (31.6) | 0 |
| **Signs and symptoms** |  |  |
| Moderate or severe ascites | 69 (51.9) | - |
| Gastrointestinal bleeding | 86 (64.7) | - |
| Hepatic encephalopathy | 31 (23.3) | - |
| **Operational parameters** |  |  |
| Anhepatic phase time (min) | 50.7 ± 9.0 | - |
| IBL (mL) | 3117 ± 1725 | - |
| IBT (mL) | 1949 ± 1749 | - |
| **Hospitalization Information** |  |  |
| Tracheal extubation time (d) | 1 (1-3) | - |
| ICU stay (d) | 2 (1-6) | - |
| Postoperative hospital stay (d) | 15 (11-23) | - |
| **Complications** |  |  |
| Massive intraoperative blood loss | 95 (71.4) | - |
| EAD caused by SFSS | 36 (27.1) | - |
| EAD caused by LFSS | 20 (15.0) | - |
| Infection | 49 (36.8) | - |
| Incision nonunion | 29 (21.8) | - |
| **Outcomes and follow-up** |  |  |
| Perioperative mortality | 29 (21.8) | - |
| Blood loss-specific mortality | 7 (5.3) | - |
| EAD-specific mortality | 17 (12.8) | - |
| All-cause mortality | 46 (34.6) | - |
| Follow-up time (mo) | 27 (9-44) | - |

Values are mean ± SD, *n* (%), or median (interquartile range).

sTLV: Standard total liver volume; eTLV: estimated total liver volume; DRI: Donor risk index; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ALD: Alcoholic liver disease; DILF: Drug-induced liver failure; IBL: Intraoperative blood loss; IBT: Intraoperative blood transfusion; ICU: Intensive care unit; EAD: Early allograft dysfunction; SFSS: Small-for-size syndrome; LFSS: Large-for-size syndrome; IQQA-3D: Intelligent/interactive qualitative and quantitative analysis-three-dimensional.

**Table 2 Univariate and multivariate logistic regression to predict massive intraoperative blood loss**

|  |  |  |
| --- | --- | --- |
|  | **Univariate** | **Multivariate** |
| **OR** | **95% CI** | ***P* value** | **OR** | **95% CI** | ***P* value** |
| Recipient age | 1.038 | 1.007-1.070 | 0.017 |  |  | 0.106 |
| Male | 0.835 | 0.336-2.074 | 0.697 |  |  | 0.815 |
| sTLVi ≥ 1.24 | 22.00 | 4.804-100.8 | < 0.001 | 18.43 | 3.809-89.15 | < 0.001 |
| Donor age | 1.014 | 0.986-1.042 | 0.340 |  |  |  |
| MD-FR combination | 1.873 | 0.650-5.396 | 0.245 |  |  |  |
| FD-MR combination | 0.698 | 0.238-2.046 | 0.513 |  |  |  |
| Graft steatosis (< 60%) | 2.187 | 0.903-5.297 | 0.083 |  |  |  |
| Cold ischemia time | 1.005 | 0.815-1.239 | 0.963 |  |  |  |
| DRI | 1.074 | 0.437-2.644 | 0.876 |  |  |  |
| HBV/HCV | 1.225 | 0.564-2.661 | 0.608 |  |  |  |
| ALD | 11.82 | 1.535-90.99 | 0.018 | 9.371 | 1.112-78.98 | 0.040 |
| DILF | 0.165 | 0.406-0.586 | 0.005 | 0.226 | 0.052-0.983 | 0.047 |
| Hepatic carcinoma | 1.422 | 0.615-3.288 | 0.410 |  |  |  |
| Gastrointestinal bleeding | 2.393 | 1.104-5.188 | 0.027 | 3.954 | 1.502-10.41 | 0.005 |
| Moderate or severe ascites | 1.065 | 0.502-2.261 | 0.869 |  |  |  |
| History of open upper abdominal surgery | 2.108 | 0.737-6.032 | 0.164 |  |  |  |
| Platelet count | 1.000 | 0.955-1.005 | 0.914 |  |  |  |
| PT | 1.011 | 0.976-1.045 | 0.577 |  |  |  |
| Child-Pugh grade C | 2.347 | 0.961-5.731 | 0.061 |  |  |  |
| MELD score | 1.012 | 0.975-1.052 | 0.526 |  |  |  |
| Anhepatic phase time | 1.020 | 0.975-1.067 | 0.396 |  |  |  |

OR: Odds ratio; 95%CI: 95% confidence interval; sTLVi: Standard total liver volume index; MD-FR: Male donor-female recipient; FD-MR: Female donor-male recipient; DRI: Donor risk index; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ALD: Alcoholic liver disease; DILF: Drug-induced liver failure; PT: Prothrombin time; MELD: Model for end-stage liver disease.

**Table 3 Univariate and multivariate logistic regression to predict early allograft dysfunction**

|  |  |  |
| --- | --- | --- |
|  | **EAD caused by SFSS** | **EAD caused by LFSS** |
| **Univariate** | **Multivariate** | **Univariate** | **Multivariate** |
| **OR** | **95% CI** | ***P* value** | **OR** | **95% CI** | ***P* value** | **OR** | **95% CI** | ***P* value** | **OR** | **95% CI** | ***P* value** |
| Recipient age | 0.980 | 0.948-1.013 | 0.235 |  |  | 0.992 | 1.062 | 1.014-1.113 | 0.012 |   |  | 0.069 |
| Male | 1.268 | 0.433-3.715 | 0.665 |  |  | 0.357 | 0.295 | 0.109-0.800 | 0.016 |  |  | 0.134 |
| sTLVi ≤ 0.85/≥ 1.32 | 175.4 | 21.85-1407 | < 0.001 | 21234 | 126-3585713 | < 0.001 | 100.3 | 16.06-970.4 | < 0.001 | 78.56 | 9.529-648.0 | < 0.001 |
| Donor age | 0.992 | 0.961-1.025 | 0.645 |  |  |  | 1.003 | 0.967-1.040 | 0.887 |  |  |  |
| MD-FR combination | 0.504 | 0.139-1.833 | 0.298 |  |  |  | 10.61 | 3.693-30.47 | < 0.001 | 6.540 | 1.617-26.45 | 0.008 |
| FD-MR combination | 0.916 | 0.242-3.464 | 0.897 |  |  |  | 1.923 | 0.557-6.637 | 0.301 |  |  |  |
| Graft steatosis (< 60%) | 0.065 | 0.009-0.502 | 0.009 |  |  | 0.444 | 2.424 | 0.923-6.368 | 0.072 |  |  |  |
| Cold ischemia time | 0.923 | 0.725-1.174 | 0.512 |  |  |  | 1.006 | 0.772-1.312 | 0.962 |  |  |  |
| DRI | 2.376 | 0.859-6.573 | 0.095 |  |  | 0.086 | 1.069 | 0.346-3.305 | 0.908 |  |  |  |
| HBV/HCV positive graft | 0.163 | 0.021-1.271 | 0.083 |  |  |  | 2.420 | 0.817-7.174 | 0.111 |  |  |  |
| HBV/HCV | 0.361 | 0.149-0.877 | 0.025 | 0.095 | 0.010-0.919 | 0.042 | 1.058 | 0.391-2.862 | 0.912 |  |  |  |
| ALD | 0.838 | 0.259-2.712 | 0.768 |  |  |  | 1.649 | 0.535-5.084 | 0.384 |  |  |  |
| DILF | 3.607 | 1.040-12.51 | 0.043 |  |  | 0.979 | 0.488 | 0.059-4.005 | 0.504 |  |  |  |
| Hepatic carcinoma | 0.480 | 0.167-1.381 | 0.173 |  |  |  | 0.493 | 0.154-1.579 | 0.234 |  |  |  |
| Hepatic encephalopathy | 1.739 | 0.667-4.534 | 0.258 |   |  |  | 3.384 | 1.249-9.167 | 0.016 |  |  | 0.186 |
| History of ALSS | 2.475 | 0.957-6.400 | 0.062 |   |  |  | 1.677 | 0.581-4.842 | 0.339 |  |  |  |
| Child-Pugh grade C | 18.85 | 2.408-147.5 | 0.005 |  |  | 0.319 | 2.200 | 0.563-8.598 | 0.257 |  |  |  |
| MELD score | 1.082 | 1.035-1.133 | 0.001 | 1.333 | 1.109-1.602 | 0.002 | 1.024 | 0.978-1.073 | 0.305 |  |  |  |
| Anhepatic phase time | 0.949 | 0.893-1.009 | 0.097 |  |  |  | 1.049 | 1.000-1.100 | 0.050 |  |  | 0.808 |

OR: Odds ratio; 95%CI: 95% confidence interval; sTLVi: Standard total liver volume index; MD-FR: Male donor-female recipient; FD-MR: Female donor-male recipient; DRI: Donor risk index; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ALD: Alcoholic liver disease; DILF: Drug-induced liver failure; PT: Prothrombin time; MELD: Model for end-stage liver disease.